Boston-area biotechs Upstream Bio and CAMP4 Therapeutics are headed to the Nasdaq on Friday, the latest companies to IPO in ...

Sanofi is ending a Phase 2 clinical trial that's testing a drug from Denali for multiple sclerosis, ending the development ...

Heart-breaking anecdotes from the patients, parents and doctors of children with the ultra-rare and fatal Barth syndrome won ...

The message over the weekend to Pfizer’s CEO Albert Bourla was blank. But it contained a warning nonetheless. It came from ...

Seven young boys treated with bluebird bio’s gene therapy for a rare neurological disease have been diagnosed with blood ...

Eli Lilly is returning to KeyBioscience, a nimble Swiss biotech, seven years after originally linking arms with the startup ...

Immatics said its PRAME-targeted T cell therapy shrank tumors by at least 30% in just over half of melanoma patients in an ...

Sen. Elizabeth Warren (D-MA) has put the spotlight on Novo Holdings’ acquisition of Catalent, expressing concerns that the ...

When Recursion Pharmaceuticals and Exscientia announced plans to merge in August, it marked the first major consolidation in ...

The activist investor targeting Pfizer claims that the company's former CEO and CFO, who were previously working with the ...

Suki, a startup that provides AI tools to help healthcare providers with documentation, billing and other administrative work ...

CDMOs are increasingly fielding inquiries from biopharma clients on how reliant they are on China for their raw materials, ...